Loading
Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia.
Inge van der Sluis is a paediatric oncologist at the Princess Máxima Center in Utrecht. She was first author of the 2023 New England Journal of Medicine report of the Interfant pilot study in which a single 28-day course of the bispecific antibody blinatumomab added to Interfant-06 chemotherapy gave two-year disease-free survival of over 80 percent in infants with KMT2A-rearranged acute lymphoblastic leukaemia, far higher than historical controls. She also studies asparaginase pharmacology.
| Title | Journal | Year |
|---|---|---|
| Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia | New England Journal of Medicine | 2023 |
Shares Princess Máxima Center for Pediatric Oncology, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.